onc Videos

Videos

David Siegel, MD, PhD, Hackensack Meridian Health

Conference Coverage

Exploring the Role of Stem Cell Transplant for Patients With Myeloma Older Than 65

04/19/2024

Featuring David Siegel, MD, PhD

Featuring David Siegel, MD, PhD ...

At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, David Siegel, MD, PhD, discusses the role of stem cell transplant for patients with myeloma over age 65 and argues that it is a viable treatment option for this patient...

At the 2024 Great Debates &...

04/19/2024

Oncology

Andrew Evens, DO, MBA, MSc, Rutgers Cancer Institute of New Jersey

Conference Coverage

Importance of Individualized Therapy, Prognostication, and Prediction in the Treatment of Hodgkin Lymphoma

04/16/2024

Featuring Andrew Evens, DO, MBA, MSc

Featuring Andrew Evens, DO, MBA, MSc ...

During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Andrew Evens, DO, MBA, MSc, speaks on the importance of targeted therapy, prognostication, and prediction when treating patients with Hodgkin lymphoma.

During the 2024 Great Debates &...

04/16/2024

Oncology

Brea Lipe, University of Rochester Medical Center

Conference Coverage

Should the Sequencing of BCMA-Directed Therapy be Used in Multiple Myeloma Treatment?

04/16/2024

Featuring Brea Lipe, MD

During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Brea Lipe, MD, argues against the utilization of sequencing BCMA-directed therapies as a treatment regimen for patients with multiple myeloma.

During the 2024 Great Debates &...

04/16/2024

Oncology

Thomas Powles, MD, MBBS, Barts Cancer Institute

Videos

Enfortumab Vedotin and Pembrolizumab Among Patients With Advanced Urothelial Cancer in the First-Line Setting

04/11/2024

Featuring Thomas Powles, MBBS, MD

Featuring Thomas Powles, MBBS, MD ...

Thomas Powles, MBBS, MD, discusses results from the phase 3 EV-302 trial, which found enfortumab vedotin plus pembrolizumab improved survival outcomes among patients with previously untreated advanced urothelial carcinoma.

Thomas Powles, MBBS, MD,...

04/11/2024

Oncology

Conference Coverage

Comparing BTK Inhibitors for Frontline Chronic Lymphocytic Leukemia Treatment

04/10/2024

Featuring John Allan, MD

John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.

John Allan, MD, compares the use...

04/10/2024

Lymphoma, Leukemia & Myeloma Network

Conference Coverage

Factors to Consider When Treating Patients With Multiple Myeloma With Bispecific Antibodies in an Outpatient Setting

04/10/2024

Featuring Ashley Rosko, MD

Ashley Rosko, MD, discusses factors to consider when administering bispecific antibody therapy to patients with multiple myeloma in an outpatient setting, which she discussed at the 2024 Great Debates & Updates in Hematologic Malignancies...

Ashley Rosko, MD, discusses...

04/10/2024

Lymphoma, Leukemia & Myeloma Network

Aditi Shastri, MD, Montefiore Einstein Comprehensive Cancer Center

Conference Coverage

Recent Updates in Risk Stratification and Treatment Methods for Patients With MDS

04/10/2024

Featuring Aditi Shastri, MD

During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Aditi Shastri, MD, shares expert insight on recent updates in risk stratification and treatment regimens for patients with low to intermediate risk myelodysplastic...

During the 2024 Great Debates &...

04/10/2024

Oncology

Conference Coverage

Is Quadruplet Therapy the New Standard of Care for Patients With Multiple Myeloma?

04/10/2024

Featuring Joseph Mikhael, MD, MEd, FRCPC, FACP

Featuring Joseph Mikhael, MD, MEd, FR...

At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Joseph Mikhael, MD, MEd, FRCPC, FACP, evaluates whether or not quadruplet therapy should be the new standard-of-care treatment for patients with multiple myeloma who are...

At the 2024 Great Debates &...

04/10/2024

Lymphoma, Leukemia & Myeloma Network

Joseph Mikhael, MD, City of Hope Cancer Center

Conference Coverage

Choosing Between CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma Treatment

04/09/2024

Featuring Joseph Mikhael, MD, MEd, FRCPC, FACP

Featuring Joseph Mikhael, MD, MEd, FR...

During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Joseph Mikhael, MD, MEd, FRCPC, FACP, shares expert insight on when to choose CAR-T therapy versus bispecific antibodies in multiple myeloma treatment.

During the 2024 Great Debates &...

04/09/2024

Lymphoma, Leukemia & Myeloma Network

Conference Coverage

Sequential Therapy vs Triplet Therapy for Patients With Newly Diagnosed AML Ineligible for Intensive Chemotherapy

04/09/2024

Featuring Jessica Altman, MD

During the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Jessica Altman, MD, argues in favor of using sequential therapy over triplet therapy for patients with newly diagnosed acute myeloid leukemia who are ineligible for...

During the 2024 Great Debates &...

04/09/2024

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology